Selective cyclooxygenase-2 inhibitors for the treatment of arthritis

Clinical Therapeutics

Volumn 21, Issue 7, 1999, Pages 1131-1157

  Fung, Horatio B ^a   Kirschenbaum, Harold L ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Celecoxib; Cyclooxygenase; Osteoarthritis; Rheumatoid arthritis; Rofecoxib

Indexed keywords

4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; AMIODARONE; CELECOXIB; CIMETIDINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; FENOPROFEN; FLOSULIDE; FLURBIPROFEN; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ROFECOXIB; SALICYLATE SODIUM; SALSALATE; SULINDAC; TOLMETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRITIS; BLOOD TOXICITY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; LIVER TOXICITY; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032777468     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80018-1     Document Type: Article

References (60)

1. 1. Polisson R. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection. Am J Med. 1996;100(Suppl 2A):31S-36S.
2. 2. Jouzeau JY, Terlain B, Abid A, et al. Cyclooxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs. 1997;53: 563-582.
3. 3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:723-731.
4. 4. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum. 1995;32:1541-1546.
5. 5. Winzeler S, Rosenstein BD. Non-steroidal antiinflammatory drugs. A review. AAOHN J. 1998;46:253-259.
6. 6. Kemppainen H, Raiha I, Sounrander L. Clinical presentation of peptic ulcer in the elderly. Gerontology. 1997;43:283-288.
7. 7. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. J Rheumatol. 1998; 25(Suppl 51):8-16.
8. 8. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol. 1998;25(Suppl 51):2-7.
9. 9. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol. 1996;25(Suppl 102):9-21.
10. 10. Richardson C, Emery P. The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf. 1996; 15:249-260.
11. 11. Bjorkman DJ. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med. 1998;105 (Suppl 1B):8S-12S.
12. 12. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol. 1997;24(Suppl 49):6-8.
13. 13. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med Res Rev. 1996;16:181-206.
14. 14. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications. Fundam Clin Pharmacol. 1996;10:1-15.
15. 15. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum. 1997;26(Suppl 1):2-10.
16. 16. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors. Gastroenterol Clin North Am. 1996;25:363-372.
17. 17. Robinson DR. Regulation of prostaglandin synthesis of antiinflammatory drugs. J Rheumatol. 1997;24(Suppl 47):32-39.
18. 18. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10.
19. 19. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997;24(Suppl 49):15-19.
20. 20. Lipsky PE. Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop. 1999;28(Suppl 3):8-12.
21. 21. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(Suppl 3A):2S-8S.
22. 22. Henry D, Lim LLY, Rodriguez LAG, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
23. 23. Stichtenoth DO. Classification of COX-1 and COX-2 inhibitors. Eur J Clin Pharmacol. 1997;52:A110. Abstract.
24. 24. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.
25. 25. Celebrex® [package insert]. Chicago, Ill: G.D. Searle & Co.; 1998.
26. 26. Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283:1069-1075.
27. 27. Hubbard RC. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med. 1996;44:293A. Abstract.
28. 28. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis in a short-term pilot study. Arthritis Rheum. 1996;39(Suppl 9):S226. Abstract.
29. 29. Zhao SZ, Hatoum HT, Hubbard RC, et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. Arthritis Rheum. 1997;40(Suppl 9):S88. Abstract.
30. 30. Hubbard RC, Geis GS, Woods E, et al. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor in osteoarthritis. Arthritis Rheum. 1998;41(Suppl 9):S196. Abstract.
31. 31. Hubbard RC, Koepp R, Yu SS, et al. Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. Arthritis Rheum. 1997;40(Suppl 9):S51. Abstract.
32. 32. Geis GS, Hubbard R, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(Suppl 9):S364. Abstract.
33. 33. Geis GS, Stead H, Morant S, et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(Suppl 9):S316. Abstract.
34. 34. Maziasz T, Seibert K, Khan N, et al. Preclinical pharmacology of celecoxib and demonstration of superior GI safety compared with NSAIDs in dogs. Arthritis Rheum. 1997;40(Suppl 9):S195. Abstract.
35. 35. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 inhibitor. Gastroenterology. 1997;112(Suppl 4):A194. Abstract.
36. 36. Lanza FL, Callison DA, Hubbard RC, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 inhibitor. Arthritis Rheum. 1997;40(Suppl 9):S93. Abstract.
37. 37. Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum. 1997;40(Suppl 9):S93. Abstract.
38. 38. Karim A, Tolbert D, Pierales A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate and warfarin. Arthritis Rheum. 1998;41(Suppl 9):S315. Abstract.
39. 39. Lane NE. Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheumatol. 1997;24(Suppl 49):20-24.
40. 40. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect? J Rheumatol. 1999;26(Suppl 56):31-36.
41. 41. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. 1998;41: 1591-1602.
42. 42. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998;37:946-951.
43. 43. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA study group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998;37:937-945.
44. 44. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol. 1996;35 (Suppl 1):68-77.
45. 45. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996;56:4566-4569.
46. 46. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58: 409-412.
47. 47. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
48. 48. Vioxx® [package insert]. West Point, Pa: Merck & Co., Inc.; 1999.
49. 49. Ehrich E, Dallob A, Van-Hecken A, et al. Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis Rheum. 1996;39(Suppl 9):S81. Abstract.
50. 50. Ehrich E, Dallob A, DeLepeleire, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999; 65:336-347.
51. 51. Ehrich E, Schnitzer T, McIlwain H, et al. MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. Osteoarthritis Cartilage. 1997;5(Suppl A):161. Abstract.
52. 52. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and the hip in a 6-week placebo-controlled study. Arthritis Rheum. 1997;40(Suppl 9):S85. Abstract.
53. 53. Saag K, Fisher C, McKay J, et al. MK-966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9):S196. Abstract.
54. 54. Cannon G, Caldwell J, Holt P, et al. MK-966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9):S196. Abstract.
55. 55. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 with MK-966 250 mg qd is associated with less gastroduodenal damage than aspirin 650 mg qid or ibuprofen 800 mg tid. Gastroenterology. 1997;112(Suppl 4):A194. Abstract.
56. 56. Hunt R, Bowen B, James C, et al. COX-2 specific inhibition with MK-966 25 or 50 mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg tid. Am J Gastroenterol. 1998;93:1670. Abstract.
57. 57. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? J Rheumatol. 1991;18:6-10.
58. 58. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
59. 59. Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial. Fam Med. 1996;28:204-210.
60. 60. Singh R, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med. 1996;156:1530-1536.